BIODESIX INC (BDSX) Stock Price & Overview
NASDAQ:BDSX • US09075X2071
Current stock price
The current stock price of BDSX is 15.07 USD. Today BDSX is up by 2.1%. In the past month the price decreased by -4.98%. In the past year, price increased by 32.1%.
BDSX Key Statistics
- Market Cap
- 148.59M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.85
- Dividend Yield
- N/A
BDSX Stock Performance
BDSX Stock Chart
BDSX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BDSX. When comparing the yearly performance of all stocks, BDSX is one of the better performing stocks in the market, outperforming 94.36% of all stocks.
BDSX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BDSX. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative.
BDSX Earnings
On February 26, 2026 BDSX reported an EPS of -0.49 and a revenue of 25.15M. The company beat EPS expectations (43.81% surprise) and missed revenue expectations (-4.17% surprise).
BDSX Forecast & Estimates
11 analysts have analysed BDSX and the average price target is 30.6 USD. This implies a price increase of 103.05% is expected in the next year compared to the current price of 15.07.
For the next year, analysts expect an EPS growth of 30.6% and a revenue growth 27.38% for BDSX
BDSX Groups
Sector & Classification
BDSX Financial Highlights
Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -4.85. The EPS increased by 30.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.31% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BDSX Ownership
BDSX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.13 | 93.495B | ||
| CI | THE CIGNA GROUP | 8.64 | 71.194B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 103.73 | 27.674B | ||
| LH | LABCORP HOLDINGS INC | 14.98 | 22.555B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.44 | 21.757B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.308B | ||
| DVA | DAVITA INC | 10.29 | 9.725B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 31.08 | 8.291B | ||
| CHE | CHEMED CORP | 15.69 | 5.241B | ||
| AGL | AGILON HEALTH INC | N/A | 4.456B | ||
| HIMS | HIMS & HERS HEALTH INC | 35.05 | 4.363B | ||
| OPCH | OPTION CARE HEALTH INC | 14.4 | 4.298B | ||
| RDNT | RADNET INC | 68.87 | 4.252B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BDSX
Company Profile
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 334 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Company Info
IPO: 2020-10-28
BIODESIX INC
919 West Dillon Road
Louisville COLORADO US
Employees: 334
Phone: 13034170500
BIODESIX INC / BDSX FAQ
Can you describe the business of BIODESIX INC?
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 334 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
What is the stock price of BIODESIX INC today?
The current stock price of BDSX is 15.07 USD. The price increased by 2.1% in the last trading session.
Does BDSX stock pay dividends?
BDSX does not pay a dividend.
What is the ChartMill rating of BIODESIX INC stock?
BDSX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of BIODESIX INC (BDSX) based on its PE ratio?
BIODESIX INC (BDSX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.85).
Should I buy BDSX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BDSX.
Can you provide the short interest for BDSX stock?
The outstanding short interest for BIODESIX INC (BDSX) is 3.33% of its float.